Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Imricor Medical Systems's current 3-Year Share Buyback Ratio was -27.10%.
The historical rank and industry rank for Imricor Medical Systems's 3-Year Share Buyback Ratio or its related term are showing as below:
ASX:IMR'
s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -27.1 Med: -17.8 Max: -10.4
Current: -27.1
During the past 8 years, Imricor Medical Systems's highest 3-Year Share Buyback Ratio was -10.40%. The lowest was -27.10%. And the median was -17.80%.
ASX:IMR's 3-Year Share Buyback Ratio is ranked worse than 83.06% of 614
companies
in the Medical Devices & Instruments industry
Industry Median: -2.6
vs ASX:IMR: -27.10
Imricor Medical Systems (ASX:IMR) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Imricor Medical Systems 3-Year Share Buyback Ratio Related Terms
ASX:IMR vs ABT, SYK, MDT: 3-Year Share Buyback Ratio Comparison
For the Medical Devices subindustry, Imricor Medical Systems's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Imricor Medical Systems 3-Year Share Buyback Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Imricor Medical Systems's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Imricor Medical Systems's 3-Year Share Buyback Ratio falls into.
Imricor Medical Systems 3-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of -27.10 mean?
Imricor Medical Systems (ASX:IMR) has a 3-Year Share Buyback Ratio of -27.10 as of Dec. 2025. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Imricor Medical Systems and its competitors. According to the industry distribution chart, Imricor Medical Systems ranks #510 out of 614 companies in the Medical Devices & Instruments industry, placing it in the top 83.1%.
Is Imricor Medical Systems' 3-Year Share Buyback Ratio too high?
Imricor Medical Systems' current 3-Year Share Buyback Ratio is -27.10. Based on the distribution chart, Imricor Medical Systems ranks #510 out of 614 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Imricor Medical Systems has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Imricor Medical Systems' 3-Year Share Buyback Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Imricor Medical Systems ranks #510 out of 614 companies for 3-Year Share Buyback Ratio. This places Imricor Medical Systems in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Medical Devices & Instruments company?
A good 3-Year Share Buyback Ratio depends on the Medical Devices & Instruments industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Imricor Medical Systems and its competitors. Imricor Medical Systems's current 3-Year Share Buyback Ratio is -27.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imricor Medical Systems stock overvalued right now?
Based on GuruFocus' analysis, Imricor Medical Systems (ASX:IMR) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.10, compared to a current price of A$1.91 — trading 1810% above its estimated fair value. The current 3-Year Share Buyback Ratio is -27.10. Imricor Medical Systems' overall GF Score™ is 39/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For Imricor Medical Systems (ASX:IMR), the current 3-Year Share Buyback Ratio is -27.10 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Imricor Medical Systems (ASX:IMR) Overvalued in 2026?
Based on GuruFocus' analysis, Imricor Medical Systems stock appears to be overvalued.
The current stock price of A$1.91 is trading 1810% above its estimated GF Value™ of A$0.10.
GuruFocus considers Imricor Medical Systems to be Significantly Overvalued.
Key valuation signals for ASX:IMR:
3-Year Share Buyback Ratio: -27.10
GF Value™: A$0.10 vs. price of A$1.91 (1810% above fair value)
No single metric tells the full story. See the ASX:IMR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Imricor Medical Systems Inc is a medical device company that develops MRI-guided technology to address issues with traditional X-ray ablation procedures. Its principal business activities are designing, manufacturing, and selling MRI-compatible products for cardiac catheter ablation procedures to treat arrhythmias. The company's products include the Advantage-MR EP Recorder/Stimulator, Vision-MR Ablation Catheter, and Vision-MR Dispersive Electrode. Geographically, the company generates maximum revenue from Europe.
39GF Score
Get the complete analysis for ASX:IMR
3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IMR has been successfully added to your 
